Highest-materiality recent filing
Enovis shareholders approve plan amendment adding 3.65M shares, raising director pay cap to $750k
Shareholders approved amendment to 2020 Omnibus Incentive Plan adding 3,650,000 shares of common stock for issuance.
Enovis Q1 net sales up 5% to $589M, net loss $8M; reaffirms FY2026 guidance
Q1 net sales $589M (+5% reported, +3% organic); Recon sales +11% reported, P&R flat.
Enovis posts FY2025 net loss of $1.18B including $1.05B goodwill impairment; Q4 sales $576M
Full-year 2025 net sales $2.2B, up 7% reported/6% organic; Recon sales +10%, P&R +4%.
Management will present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
Enovis CHRO Patricia Lang to retire; Laura Singleton appointed successor
Patricia Lang will step down as SVP & CHRO effective April 3, 2026, transitioning to advisory role until April 3, 2027.
Enovis amends credit agreement; extends maturity to 2030, upsizes cash offset to $400M
Amended credit agreement provides $1.1B revolver and $700M term loan, both maturing Dec 8, 2030.
Enovis EVP Strategy & Business Dev Pryor steps down; advisory role through Mar 2026
Daniel A. Pryor departed as EVP Strategy and Business Development on Nov 7, 2025; position eliminated.
Enovis Q3 sales up 9% to $549M; raises FY adjusted EBITDA and EPS guidance
Q3 net sales $549M (+9% reported, +7% organic); Recon +12% reported, P&R +6% reported.
Enovis Q2 revenue up 7%, guided FY25 higher; adjusted EPS $0.79
Net sales $565M (+7% reported, +5% organic); Recon +11%, P&R +5%.
Enovis shareholders elect nine directors, ratify auditor, approve say-on-pay at annual meeting
All nine director nominees elected; For votes ranged from 49.6M to 50.4M shares (broker non-votes 1.7M each).
Enovis Q1 revenue +8% to $559M; adjusted EBITDA margin 17.7% (+160bps); appoints Damien McDonald CEO
Q1 net sales $559M, +8% reported; Recon +11%, P&R +5% YoY.
Enovis appoints Damien McDonald as CEO effective May 12; Q1 guidance reaffirmed
Damien McDonald, former LivaNova CEO, appointed CEO effective May 12, 2025; succeeds retiring CEO Matt Trerotola.
CEO Matthew Trerotola's retirement effective when successor appointed; transition agreement signed March 13, 2025.
Enovis CEO Matt Trerotola to retire; board begins search for successor
CEO Trerotola retiring upon successor appointment; will serve as Executive Advisor for one year.
Enovis Q4 net loss $704M on $645M goodwill impairment; CEO plans retirement
Q4 revenue $561M (+23% reported, +6% comparable); Recon sales +59% reported.
Enovis files prospectus supplement to register 971,343 shares for resale by Emil
Second tranche of 971,343 shares issued to Emil on Jan 15, 2025 as part of Lima acquisition consideration.
Enovis to present at J.P. Morgan Healthcare Conference on Jan 13, 2025
CEO Matt Trerotola and CFO Ben Berry present at the conference at 9:45 AM PST.
Q3 net sales $505M, up 21% reported/6% comparable; Recon sales +57% reported/9% comparable.
Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77
Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.
Enovis files resale registration for 971,343 shares issued to former Lima shareholder
Filed prospectus supplement for resale of 971,343 shares of common stock held by Emil Holding II.
Stockholders approved amendment adding 2,100,000 shares to the 2020 Omnibus Incentive Plan for future awards.
Enovis Q1 revenue $516M (+27% YoY), adjusted EPS $0.50, raises full-year outlook
Net sales of $516M, up 27% reported and 5% proforma YoY; Recon sales +66% reported, +7% proforma.
appointed Mr. McDonald as a member of the Board to fill the vacancy resulting from Mr. Trerotola’s retirement from the Board.
the Board has (i) appointed Sharon Wienbar, who has served as the Lead Independent Director of the Board since May 2023, to serve as independent Chair of the Board
Matthew L. Trerotola, the Company’s current CEO, will retire from such role as of the Appointment Date
the Board of Directors of the Company (the “Board”) has appointed Damien McDonald as Chief Executive Officer (“CEO”) of the Company, effective as of May 12, 2025
As previously announced by Enovis Corporation (the “Company”), on February 25, 2025, Matthew L. Trerotola notified the Board of Directors (the “Board”) of the Company of his intention to retire from his current position as Chief Executive Officer (“CEO”) of the Company, effective upon his successor being appointed by the Board and assuming the position as CEO of the Company (the “Appointment Date”).
On February 25, 2025, Matthew L. Trerotola notified the Board of Directors (the “Board”) of Enovis Corporation (the “Company”) of his intention to retire from his current position as Chief Executive Officer (“CEO”) of the Company, effective upon his successor being appointed by the Board and assuming the position as CEO of the Company.
Max materiality 0.85 · Median 0.62 · Most common event earnings